title: The prognostic value of p53 immunostaining in node-negative breast carcinoma.
abstract: BACKGROUND
  P53 plays a key role in cell cycle arrest, apoptosis, DNA repair, and angiogenesis. Although some studies have reported as prognostic factor for poor survival in node-positive breast cancer, controversy about possible prognostic index for node-negative still exists.
  
  
  OBJECTIVE
  To look for correlations between the expression of the p53 protein and clinicopathological parameters, and to assess its prognostic value in node-negative invasive ductal breast carcinoma.
  
  
  METHODS
  Immunohistochemistry using formalin-fixed, paraffin-embedded sections from 71 node-negative breast carcinomas in Songklanagarind Hospital. Data were analyzed with respect to tumor size, estrogen receptor, and survival.
  
  
  RESULTS
  P53 mutations were found in 12 patients (17%). Expression of p53 was not associated with tumor size, estrogen receptor, and overall survival. Mean follow-up time was 164.4 months (median 163 months).
  
  
  CONCLUSIONS
  P53 expression was not a significant prognostic factor for survival in node-negative breast carcinoma.
authors.affiliation: Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
authors.forename: Prinya
authors.initials: P
authors.lastname: Soontrapornchai
authors.forename: Apinop
authors.initials: A
authors.lastname: Chanvitan
authors.forename: Sittichai
authors.initials: S
authors.lastname: Koontongkaew
authors.forename: Somkiat
authors.initials: S
authors.lastname: Sunpaweravong
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D005260:Female; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D006305:Health Status Indicators; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D011446:Prospective Studies; D011960:Receptors, Estrogen; D013534:Survival
chemical_list: D011960:Receptors, Estrogen